Want to see SPRB full AI Analyst Report?
SPRB Stock Chart & Stats
$43.08
-$1.91(-4.25%)
At close: 4:00 PM EDT
$43.08
-$1.91(-4.25%)
Day’s Range― - ―
52-Week Range$7.00 - $240.00
Previous CloseN/A
Volume106.73K
Average Volume (3M)80.64K
Market Cap
$117.88M
Enterprise Value$42.71
Total Cash (Recent Filing)$54.08M
Total Debt (Recent Filing)$7.12M
Price to Earnings (P/E)―
Beta-10.13
Next Earnings
Aug 17, 2026EPS Estimate
-5.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-37.60
Shares Outstanding2,752,278
10 Day Avg. Volume71,536
30 Day Avg. Volume80,640
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.57
Price to Sales (P/S)0.00
P/FCF Ratio-2.00
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$152.57Price Target Upside254.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-24.58
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical LeadershipHiring an experienced CMO with a track record of advancing and launching rare disease therapies strengthens clinical development execution, regulatory strategy, and trial design. Over months this raises the probability of smoother development, clearer regulatory interactions, and stronger partner interest.
Low LeverageVery low debt reduces interest burden and short-term default risk, giving management financial flexibility to prioritize R&D decisions. This structural balance-sheet strength buys time for clinical milestones and potential partnering without immediate pressure from creditors.
Niche Rare-disease FocusA focused pipeline targeting CAH and hormone-driven disorders provides structural advantages: high barriers to entry, specialized regulatory pathways, and potential orphan drug incentives. This durable strategic positioning increases long-term partner and payer interest if clinical success occurs.
Bears Say
No Recent RevenueAbsence of recurring product revenue means the business relies entirely on financing and milestones, not commercial cash flow. Over the coming months this keeps the company exposed to capital market cycles and makes long-term sustainability contingent on clinical success or financing events.
Persistent Cash BurnSustained negative operating and free cash flow indicates the company is consuming cash at a material rate. This structurally shortens runway absent new capital or partnering, forcing dilutive equity raises or strategic tradeoffs that can constrain development pacing and portfolio flexibility.
Ongoing Losses & Equity ErosionPersistent net losses and declining shareholder equity signal that investment has not yet translated to value creation. Over months this weakens financial cushions, can increase cost of capital, and heightens execution risk as future financing may be more dilutive or come with restrictive terms.
Spruce Biosciences News
SPRB FAQ
What was Spruce Biosciences, Inc.’s price range in the past 12 months?
Spruce Biosciences, Inc. lowest stock price was $7.00 and its highest was $240.00 in the past 12 months.
What is Spruce Biosciences, Inc.’s market cap?
Spruce Biosciences, Inc.’s market cap is $117.88M.
When is Spruce Biosciences, Inc.’s upcoming earnings report date?
Spruce Biosciences, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 15 days.
How were Spruce Biosciences, Inc.’s earnings last quarter?
Spruce Biosciences, Inc. released its earnings results on May 13, 2026. The company reported -$8.94 earnings per share for the quarter, missing the consensus estimate of -$7.934 by -$1.006.
Is Spruce Biosciences, Inc. overvalued?
According to Wall Street analysts Spruce Biosciences, Inc.’s price is currently Undervalued.
Does Spruce Biosciences, Inc. pay dividends?
Spruce Biosciences, Inc. does not currently pay dividends.
What is Spruce Biosciences, Inc.’s EPS estimate?
Spruce Biosciences, Inc.’s EPS estimate is -5.79.
How many shares outstanding does Spruce Biosciences, Inc. have?
Spruce Biosciences, Inc. has 2,752,278 shares outstanding.
What happened to Spruce Biosciences, Inc.’s price movement after its last earnings report?
Spruce Biosciences, Inc. reported an EPS of -$8.94 in its last earnings report, missing expectations of -$7.934. Following the earnings report the stock price went up 1.562%.
Which hedge fund is a major shareholder of Spruce Biosciences, Inc.?
Currently, no hedge funds are holding shares in SPRB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Spruce Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$152.57 (254.16% Upside)
$152.57 (254.16% Upside)
Blogger Sentiment
Bullish
SPRB Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 16.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
370.81%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
77.47%
Trailing 12-Months
Company Description
Spruce Biosciences, Inc.
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
SPRB Stock 12 Month Forecast
Average Price Target
$152.57
▲(254.16% Upside)
Technical Analysis
Ownership Overview
1.08% Insiders
1.04% Mutual Funds
12.90% Other Institutional Investors
75.94% Public Companies and
Individual Investors